GLP1R and Obesity: Finally, only a small proportion of our cohort trialed weight loss medications prior to MBS, and, given the data supporting the efficacy of glucagon-like peptide-1 receptor agonists in adolescents with obesity (55), further work is now required to definitively establish the role for pharmacotherapy in bridging the gap between diet and lifestyle interventions and weight loss surgery.